Cargando…

Vedolizumab in the treatment of Crohn’s disease of the pouch

BACKGROUND: Our recent study showed the efficacy and safety of vedolizumab in the treatment of chronic antibiotic-refractory pouchitis. However, there are no published studies on its efficacy and safety in Crohn’s disease (CD) of the pouch. The aim of this study was to assess the efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Freeha, Gao, Xian-Hua, Singh, Amandeep, Philpott, Jessica R, Shen, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6101609/ https://www.ncbi.nlm.nih.gov/pubmed/30151202 http://dx.doi.org/10.1093/gastro/goy014

Ejemplares similares

Vedolizumab for chronic antibiotic-refractory pouchitis
por: Singh, Amandeep, et al.
Publicado: (2019)

Diagnosis and management of floppy pouch complex
por: Khan, Freeha, et al.
Publicado: (2018)

Combined Endoscopic Fistulotomy and Clipping for the Treatment of Fistula From the Tip of the J-Pouch to Anastomosis
por: Sze, Grace, et al.
Publicado: (2019)

The Use of Vedolizumab in Patients with Concomitant Cirrhosis and Crohn’s Disease
por: Kapila, Nikhil, et al.
Publicado: (2018)

Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease
por: Holmer, Ariela K., et al.
Publicado: (2020)

Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
por: Zhou, Ting, et al.
Publicado: (2021)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Vedolizumab for induction and maintenance of remission in Crohn's disease
por: Hui, Samuel, et al.
Publicado: (2023)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
por: Gilroy, Leah, et al.
Publicado: (2014)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis
por: Ayoub, Fares, et al.
Publicado: (2022)

Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
por: Yajnik, Vijay, et al.
Publicado: (2017)

Vedolizumab (Entyvio®) for the Treatment of Pyoderma Gangrenosum in a Crohn’s Disease Patient
por: Groudan, Kevin, et al.
Publicado: (2021)

Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients
por: Gebeyehu, Gerum Gashaw, et al.
Publicado: (2022)

Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab
por: Yeh, Jennifer E., et al.
Publicado: (2017)

Safety and Efficacy of Vedolizumab in Kidney Transplant Recipients With Crohn’s Disease
por: Busutti, Marco, et al.
Publicado: (2023)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Endoscopic Sinusotomy Using Needle Knife Technique for Treatment of H-Pouch With Leak and Sinus
por: Khoudari, George, et al.
Publicado: (2019)

Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis
por: Moćko, Paweł, et al.
Publicado: (2016)

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
por: Okamoto, Hiroyuki, et al.
Publicado: (2021)

Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab
por: Petkau, Jill MV, et al.
Publicado: (2016)

Orbital Myositis in a Patient With Ileal Crohn's Disease in Remission on Vedolizumab
por: Sandhu, Sunny, et al.
Publicado: (2022)

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease
por: Dulai, Parambir S., et al.
Publicado: (2019)

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis
por: Faleck, David M., et al.
Publicado: (2019)

Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study
por: Banerjee, Rupa, et al.
Publicado: (2021)

Vedolizumab in Crohn’s disease with rectal fistulas and presacral abscess: A case report
por: Yeh, Heng, et al.
Publicado: (2021)

Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario
por: Zingone, Fabiana, et al.
Publicado: (2020)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
por: Newman, Kira L., et al.
Publicado: (2023)

AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE
por: Macaluso, F.S., et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
por: Holko, Przemysław, et al.
Publicado: (2018)

Prophylactic Treatment with Vedolizumab in the Prevention of Postoperative Recurrence (POR) in High-Risk Crohn’s Patients
por: Frieri, Giuseppe, et al.
Publicado: (2023)

Efficacy of Vedolizumab in Fistulising Crohn’s Disease: Exploratory Analyses of Data from GEMINI 2
por: Feagan, Brian G, et al.
Publicado: (2018)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

Value of routine stool testing for pathogenic bacteria in the evaluation of symptomatic patients with ileal pouches
por: Singh, Amandeep, et al.
Publicado: (2018)

CT or MR Enterography to Assess Response During Vedolizumab Therapy for Small Bowel Crohn’s Disease
por: Kwapisz, Lukasz, et al.
Publicado: (2022)

IT Knife-Assisted Balloon Stricturoplasty in a Patient With Crohn's Disease
por: Singh, Kevin, et al.
Publicado: (2020)

Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn’s Disease: A Post Hoc Analysis of GEMINI 2 and 3
por: Sands, Bruce E, et al.
Publicado: (2019)

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
por: Biemans, Vince B. C., et al.
Publicado: (2020)

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?
por: Card, Timothy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4qf36l33htfvd5agd2vqlqhdj6